111 Capital’s Viking Therapeutics VKTX Stock Holding History

111 Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,474	Closed	-$384K	–	700
2025 Q2	$384K	Buy	14,474 +5,559	+62%	+$146K	0.07%	302
2025 Q1	$215K	Buy	+8,915	New	+$282K	0.04%	395

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

111 Capital's VKTX Position: Q3 2025 in Review

111 Capital sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 14,474 shares — an estimated $384K sold.

111 Capital first reported a position in VKTX in Q1 2025 and held it in 2 quarters. The position peaked at $384K in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

111 Capital reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
111 Capital sold 14,474 Viking Therapeutics shares in Q3 2025, an estimated $384K.
111 Capital first reported a position in Viking Therapeutics in Q1 2025 and held it in 2 quarters.
111 Capital's Viking Therapeutics position peaked at $384K in Q2 2025.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.